jama glp-1 📌 Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no "What we really need to

A new label for a new market In the frozen food section of a supermarket near Washington, D.C., recently, Wiseman examined the labeling on one such item Healthy Choice brand's Cajun shrimp and chicken dinner

Phase 2 trial (NEJM 2023) used a structured ramp to 12 mg/week but at trial doses of 8 mg and 12 mg, dropout from gastrointestinal events was substantial

With a $20m market cap and no debt, iBio is essentially a pure bet that a leading cardiometabolic team + aligned investors will be able to develop and partner on an attractive myostatin inhibition compound before 2026

Neuropsychologia, 41, 184-194

Certain groups may need to take a B12 supplement for life

Standard oral glutathione products tend to be poorly absorbed due to the action of an intestinal enzyme which has the potential to degrade glutathione